Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

19h ago, source:

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ...

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

1d ago, source:

Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its ...

Aligos Therapeutics gets grant for treatment of disease using compounds of formula i

8d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent granted to Aligos Therapeutics Inc for compounds of Formula I, paving the way for innovative treatments and pharmaceutical compositions. Explore the potential of ...

Aligos Therapeutics describes new prodrugs to treat hepatitis B and D virus infections

4d ago, source: BioWorld

Aligos Therapeutics Inc. has identified prodrugs reported to be useful for the treatment of hepatitis B and hepatitis D viral infections.

A Gaithersburg firm just secured $35M from a longtime backer

1d ago, source: The Business Journals

Immunomic Therapeutics Inc., a cancer therapy company based in Rockville, similarly has raised multiple batches of funding in ...

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

1d ago, source: Zacks.com on MSN

Wall Street expects a year-over-year increase in earnings on higher revenues when Omega Therapeutics, Inc. (OMGA) reports results for the quarter ended March 2024. While this widely-known consensus ...

Omega Therapeutics Inc (OMGA): A Technical Analysis

7mon ago, source: newsheater

Based on Omega Therapeutics Inc (OMGA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio ...